NCT03149315View on ClinicalTrials.gov

Inhibition of Anaphylaxis by Ibrutinib

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Food AllergyAnaphylaxis Food
Interventions
DRUG

Ibrutinib

Ibrutinib 420mg, PO once daily for 2-7 days

Trial Locations (1)

60611

Ann & Robert H. Lurie Childrens Hospital of Chicago, Chicago

All Listed Sponsors
collaborator

Northwestern University Feinberg School of Medicine

OTHER

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

NCT03149315 - Inhibition of Anaphylaxis by Ibrutinib | Biotech Hunter | Biotech Hunter